Chapters authored
Human Immunodeficiency Virus-Hepatitis B Virus (HIV-HBV) Coinfection
The global epidemics of hepatitis B and HIV have led to a new understanding of the complex interactions between these two viruses. Due to similar patterns of contamination, the high prevalence of HBV infection among the 33 million people living with HIV (PLHIV) across the world is about 10%. In highly endemic areas such as sub-Saharan Africa, this prevalence can be as high as 15% and leads us systematically to seek HIV/HBV co-infection. According to WHO, nearly 240 million people are chronically infected with HBV worldwide. Of these, 4 million are co-infected with HIV. Overall, co-infection rates range from 5 to 14% in areas of low prevalence of HBV infection and 5–73% in areas of high prevalence for HBV infection. Studies have revealed the complexity of the infection relationship between HIV and HBV. This complex relationship is thought to be responsible for greater morbidity and mortality of hepatic origin in co-infected patients than in mono-infected individuals. This chapter will highlight the following main points: Concomitant negative impact of HIV and HBV on their natural histories Implication of concomitant negative impact on the overall management of HIV-HBV coinfection Treatment and management.
Part of the book: Advances in HIV and AIDS Control